News

Stop TB Partnership’s Coordinating Board Meets in DC

Today was the opening of the 2-day Stop TB Partnership’s Coordinating Board (CB) meeting in Washington, D.C. which included welcoming remarks by Dr. Rajiv Shah (Administrator, USAID), Ms. Lois Quam (Executive Director, GHI), and Dr. Howard Koh (Assistant Secretary, U.S. Depart. of HHS). Having the meeting in the capital of the U.S. has been a great advocacy opportunity to help reinforce the commitment of the U.S. Government and partners to allocating resources to tuberculosis. During the days preceding the CB meeting, several high level missions were organized with heads of U.S. agencies and the esteemed Ministers of Health from South Africa, Lesotho, and Swaziland.

The board meets biannually to provide leadership and direction, to monitor the implementation of agreed policies, to plan activities of the Partnership, and to ensure coordination among Stop TB Partnership components. The Working Group on New Drugs is represented on the board.

Links to related news:

Southern African “A-Team” takes on TB

India: As the middle class rises, so does tuberculosis

SA nursing still plagued by many challenges

Motsoaledi forms partnership with American agencies

More funding for TB research and development needed, new report says

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...